Dense Breast Tissue Screenings:
HB 131 creates a new section of Florida Statutes governing dense breast tissue screenings. It provides that a patient who has previously been identified as having dense breast tissue in a mammography report may receive an ultrasound or other additional screening tests without first having to obtain a conventional mammogram. The bill defines “mammography report” by reference to federal regulation and sets an effective date of July 1, 2025.
In practical terms, the bill would expand access to supplemental breast cancer screening for patients with dense breast tissue, allowing them to proceed directly to ultrasound or other follow-up imaging when clinically appropriate. The measure is narrowly focused on screening access and does not create a broader insurance mandate or general breast cancer treatment program in the text provided.
The bill would add section 381.94 to the Florida Statutes and establish a state-level rule permitting additional breast screening tests for patients previously identified as having dense breast tissue. It would affect patients, radiology providers, and mammography practices by clarifying that a conventional mammogram is not required before obtaining an ultrasound or other supplemental screening. Because the bill died in the Health Care Facilities & Systems Subcommittee, it did not become law and therefore did not change existing statutory requirements.
The available record suggests generally favorable policy intent, as the bill addresses a common breast health concern and seeks to improve screening access for patients with dense breast tissue. However, there are no committee transcripts or recorded votes provided, so there is no detailed evidence of debate, support, or opposition in the materials supplied. Its failure to advance out of subcommittee indicates it did not secure enough legislative momentum to move forward.
The main policy issue is whether patients with dense breast tissue should be able to obtain supplemental screening directly, without first undergoing a conventional mammogram. Supporters would likely view the bill as improving early detection and patient access to appropriate imaging, while potential critics could question medical necessity, cost, or how the screening pathway should be structured. Because no transcripts or votes are available, specific objections or named opponents are not identified in the record provided.